title: Can intravitreal ranibizumab alter retrobulbar circulation in eyes with age-related macular degeneration?
abstract: OBJECTIVE
  To determine the effect of a single intravitreal ranibizumab injection on retrobulbar circulation in cases with neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  In this prospective and interventional study, 32 patients with neovascular AMD were enrolled. A single intravitreal ranibizumab dose was in only 1 eye per patient. Peak systolic velocity, end-diastolic velocity, resistive index and pulsatility index values in the common carotid artery, ophthalmic artery, central retinal artery, nasal posterior ciliary artery, and temporal posterior ciliary artery in both injected and uninjected healthy fellow eyes were measured using color Doppler ultrasonography at baseline and 1 week and 1 month after the injection of ranibizumab.
  
  
  RESULTS
  All measurements revealed no statistically significant difference among baseline, first week, and first month after injection measurements for all parameters measured in all arteries in both the injected and uninjected healthy fellow eyes.
  
  
  CONCLUSIONS
  A single intravitreal injection of ranibizumab does not significantly affect on retrobulbar circulation of either the injected or the uninjected healthy fellow eyes with neovascular AMD.
authors.affiliation: 1 Department of Ophthalmology, Beyoglu Eye Research and Education Hospital , Istanbul, Turkey .
authors.forename: Kemal
authors.initials: K
authors.lastname: Yuksel
authors.forename: Hasan
authors.initials: H
authors.lastname: Altinkaynak
authors.forename: Adnan
authors.initials: A
authors.lastname: Kina
authors.forename: Necip
authors.initials: N
authors.lastname: Kara
authors.forename: Ahmet Taylan
authors.initials: AT
authors.lastname: Yazici
authors.forename: Ahmet
authors.initials: A
authors.lastname: Demirok
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D062186:Arterial Pressure / Q000187:drug effects; D001783:Blood Flow Velocity / Q000187:drug effects; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005123:Eye / Q000098:blood supply*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D012039:Regional Blood Flow / Q000187:drug effects*; D018615:Ultrasonography, Doppler, Color
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab